|
Imaging Biometrics Ltd shares fell on Friday, after it said it will no longer proceed with an intended phase 2 trial of gallium maltolate. The stock tumbled 33% to 0.57 pence on Friday afternoon in London. The London-based healthcare imaging software company sponsored a phase 1 trial evaluating oral gallium maltolate for the treatment of recurrent glioblastoma in early 2022. However, Imaging Biometrics said it is no longer in shareholders’ interests to embark on a phase 2 trial, as previously intended. Instead, it said: ‘The financial and operational resources would be better employed to concentrate upon nearer-term commercial objectives of our imaging solutions.’ IBAI said that the phase 1 study remains open, with one patient still receiving treatment, but enrollment was closed in November, and the authors are preparing the results for submission to a peerreviewed journal. IBAI noted that it still holds two orphan drug designations, two rare pediatric disease designations, and a US Food & Drug Administration ’Fast Track’ designation. All of these, it said, ‘remain valuable assets that preserve future optionality’. IBAI also highlighted the GABRIEL pediatric trial of gallium maltolate in Wisconsin and said that although it is not formally involved, it will monitor the study’s progress as any developments ‘may help inform the broader landscape of research related to gallium maltolate’. ‘Our decision reflects a disciplined commitment to focus-ensuring that we invest where we can deliver the greatest value for patients, clinicians, and shareholders in the near term,’ IBAI said. ‘The imaging business is promising stronger commercial performance, expanding clinical adoption, and increasing recognition for its technological differentiation. ‘Concentrating our efforts here allows us to build on this momentum and continue scaling in a way that strengthens the company’s financial foundation and longterm outlook.’ Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
